This can, in part, explain the improved response rates and survival noted in patients with obesity across different tumor types who are treated with ICI including PD-1/PD-L1 (programmed death ligand-1) inhibitors that target the interaction of these checkpoint receptors (52–54). Here, CD274 is linked to obesity due to melanocortin 4 receptor deficiency.